Biocon gets nod to raise up to Rs 600 crore through commercial papers

05 Apr 2025 Evaluate

Biocon has received approval for issuance of commercial papers up to an amount not exceeding Rs 600 crore in one or more tranches on private placement basis. The Board of Directors at its meeting held on April 04, 2025, has approved the same.

Earlier, the company’s wholly owned subsidiary -- Biocon Pharma had received approval from the U.S Food and Drug Administration (USFDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

398.05 -3.35 (-0.83%)
24-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1737.50
Dr. Reddys Lab 1266.35
Cipla 1496.35
Zydus Lifesciences 917.45
Lupin 2109.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×